Sunshine Biopharma (NASDAQ:SBFM) filed its Form 10-K for fiscal 2025, reporting $36.31 million revenue, a 4.1% increase versus 2024. Gross profit rose to $12.26 million while net loss widened to $5.98 million.
The company raised $2.46 million via a registered direct offering, launched nine new generic drugs, recorded a $1.75 million non‑cash impairment, and announced planned 2026 cost reductions of approximately $2–3 million.
Loading...
Loading translation...
Positive
Gross profit increased to $12.26M (+14.9%)
Registered direct offering raised $2.46M to support sales expansion
Nine generic drug launches expanded portfolio across multiple therapeutic areas
Negative
General & administrative expenses rose to $18.48M (+12.1%)
Net loss increased to $5.98M (+16.6%)
$1.75M impairment boosted 2025 non‑cash charges
News Market Reaction – SBFM
+11.54%
10 alerts
+11.54%Session close to close
+14.5%Peak Tracked
-7.1%Trough Tracked
$5.75MMarket Cap
1.4xRel. Volume
In the Apr 6 session, SBFM gained 11.54%, reflecting a significant positive market reaction.
Argus tracked a peak move of +14.5% during that session.
Argus tracked a trough of -7.1% from its starting point during tracking.
Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
The stock surged +11.5% in the session following this news. A strong positive reaction aligns with S...
Analysis
The stock surged +11.5% in the session following this news. A strong positive reaction aligns with Sunshine Biopharma’s historical pattern of favorable responses to earnings that show revenue growth. Prior results with double-digit gains followed announcements of rising sales and improving losses. However, ongoing net losses of $5.98M in 2025 and elevated G&A expenses, including a $1.75M impairment, highlight execution and cost-control risks that could cap upside if growth slows or cost reductions of $2M–$3M are not achieved.
Key Figures
2025 Revenue:$36.31MRevenue Growth:4.1%2025 Gross Profit:$12.26M+5 more
8 metrics
2025 Revenue$36.31MFiscal 2025 vs $34.87M in 2024
Revenue Growth4.1%Fiscal 2025 vs 2024
2025 Gross Profit$12.26MFiscal 2025 vs $10.67M in 2024
2025 Net Loss$5.98MFiscal 2025 vs $5.13M in 2024
G&A Expenses 2025$18.48MIncludes non-cash impairment; vs $16.48M in 2024
Impairment Charge$1.75MNon-cash, non-recurring intangible asset impairment in 2025
Capital Raised$2.46MGross proceeds from registered direct offering for sales expansion
Planned Cost Reductions$2M–$3MExpected 2026 G&A expense reduction from initiatives
Q1 2024 gross revenues up 54% and net loss improved, but shares fell sharply.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Earnings releases have often been received positively despite ongoing losses, with only one notable negative divergence where strong top-line growth coincided with a sharp price decline.
Recent Company History
Recent earnings for Sunshine Biopharma show consistent revenue growth but persistent net losses. Prior reports highlighted strong year-over-year revenue gains in 2024 and 2025 quarters, improving or mixed net loss trends, and expanding generic launches via Nora Pharma. Market reactions have usually been favorable, with several earnings days posting double-digit gains, though one 2024 first-quarter release saw a 17.8% drop despite higher revenues. Today’s modest full-year 4.1% revenue increase and higher net loss fit into this pattern of growth tempered by elevated expenses.
Key Terms
registered direct offering, non-covalent, plpro protease inhibitors, sars-cov-2, +3 more
7 terms
registered direct offeringfinancial
"$2.46 million in gross proceeds raised through a registered direct offering..."
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
non-covalentmedical
"a new series of orally active, non-covalent PLpro protease inhibitors..."
Non-covalent describes a type of interaction where molecules stick together through weak, reversible forces rather than forming permanent chemical bonds. For investors, non-covalent binding in drugs or diagnostics signals treatments that are often adjustable, shorter-acting, and potentially easier to reverse or fine-tune than covalent counterparts, which affects safety profiles, dosing strategies, patenting approaches and how a product may perform in the market.
plpro protease inhibitorsmedical
"non-covalent PLpro protease inhibitors that demonstrated dose-dependent antiviral activity..."
PLpro protease inhibitors are drugs that block the papain-like protease (PLpro), an enzyme some viruses use to process their proteins and weaken the body's defenses. For investors, they matter because a proven PLpro inhibitor can become a targeted antiviral treatment with clear regulatory and commercial implications, while setbacks in development influence clinical risk, approval timelines and potential market value—think of them as tools that jam a virus’s internal machinery.
sars-cov-2medical
"dose-dependent antiviral activity in SARS-CoV-2-infected mice, strong potency..."
SARS-CoV-2 is the virus that causes the illness known as COVID-19; think of it as a biological engine that can start chains of sickness in people. It matters to investors because its spread and the measures taken to control it—such as changes to workforce availability, consumer demand, supply chains, travel, and healthcare spending—can quickly alter company revenues, costs and regulatory priorities, much like a sudden storm that affects many parts of an economy at once.
pharmacokineticsmedical
"strong potency in cellular models, and favorable pharmacokinetics."
Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.
form 10-kregulatory
"announced the filing of its Annual Report on Form 10-K for the fiscal year..."
A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.
impairment chargefinancial
"driven by a non-cash, non-recurring impairment charge of $1.75 million..."
An impairment charge is an accounting write-down taken when a company determines an asset—like a building, patent, or investment—is worth less than its recorded value, similar to lowering the price tag on a used car when damage reduces its resale value. It matters to investors because it reduces reported profits and the company’s asset base, can signal business challenges or one-time losses, and may affect future earnings, creditworthiness, and valuation.
FORT LAUDERDALE, FL / ACCESS Newswire / April 6, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("Sunshine Biopharma" or the "Company"), a pharmaceutical company offering and developing life‑saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the filing of its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025.
2025 Highlights
Revenue of $36.3 million, representing a 4.1% increase compared to 2024.
$2.46 million in gross proceeds raised through a registered direct offering to support expansion of sales operations.
Nine new generic prescription drugs launched, expanding the Company's portfolio in oncology, cardiovascular health, central nervous system disorders, and antimicrobials.
Advancement of proprietary antiviral research, including a new series of orally active, non‑covalent PLpro protease inhibitors that demonstrated dose‑dependent antiviral activity in SARS‑CoV‑2‑infected mice, strong potency in cellular models, and favorable pharmacokinetics.
Management Commentary
"We are pleased with our accomplishments in 2025, as we remain committed to reaching profitability in the near future," said Dr. Steve Slilaty, CEO. "Looking ahead, we are excited about the opportunities for growth in 2026 and beyond as we continue expanding our generic drug portfolio and advancing our proprietary drug development programs to deliver more life‑saving medicines to the market."
Financial Summary (in millions)
2025
2024
Revenue
$36.31
$34.87
Gross Profit
$12.26
$10.67
General & Administrative Expenses
$18.48
$16.48
Net Loss
$5.98
$5.13
The increase in General & Administrative Expenses in 2025 was primarily driven by a non‑cash, non‑recurring impairment charge of $1.75 million related to intangible assets. Excluding this charge, the Company's operating performance reflects a meaningful improvement over 2024.
In January 2026, Sunshine Biopharma implemented cost‑reduction initiatives aimed at lowering general and administrative expenses and sharpening the Company's focus on achieving near‑term profitability. Based on current plans, these initiatives are expected to reduce expenses by approximately $2 million to $3 million in 2026, although there can be no assurance that these reductions will be fully realized.
About Sunshine Biopharma
Sunshine Biopharma currently markets 71 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026. The Company is also advancing two proprietary drug development programs:
K1.1 mRNA, an mRNA‑Lipid Nanoparticle therapeutic candidate targeting liver cancer.
PLpro protease inhibitor, a small‑molecule antiviral candidate for SARS‑related coronavirus infections.
This press release contains forward‑looking statements based on current expectations, forecasts, and assumptions that involve risks and uncertainties. These statements include, but are not limited to, those regarding the Company's financial performance, drug development activities, and future growth opportunities. Actual results may differ materially due to various risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission. Readers are encouraged to review the Company's most recent SEC filings for additional information.
What were Sunshine Biopharma (SBFM) fiscal 2025 revenue and net loss reported on April 6, 2026?
Sunshine Biopharma reported $36.31 million in revenue and a $5.98 million net loss for fiscal 2025. According to the company, revenue rose 4.1% year‑over‑year while net loss widened versus 2024.
How much did Sunshine Biopharma (SBFM) raise in the January 2026 registered direct offering and why?
The company raised $2.46 million in a registered direct offering to support expansion of sales operations. According to the company, proceeds will help scale commercial efforts and portfolio growth.
What drove the increase in Sunshine Biopharma's (SBFM) general and administrative expenses in 2025?
A non‑cash, non‑recurring $1.75 million impairment to intangible assets largely drove higher G&A in 2025. According to the company, this charge materially increased reported expenses versus 2024.
What cost reductions did Sunshine Biopharma (SBFM) announce for 2026 and what are the expected savings?
Sunshine Biopharma implemented cost‑reduction initiatives expected to lower expenses by $2–3 million in 2026. According to the company, these actions target general and administrative expense reductions to improve profitability.
How many new generic drugs did Sunshine Biopharma (SBFM) launch in 2025 and which areas do they cover?
Sunshine Biopharma launched nine new generic prescription drugs in 2025 across oncology, cardiovascular, CNS disorders, and antimicrobials. According to the company, these launches expand its commercial portfolio.
What progress did Sunshine Biopharma (SBFM) report on its antiviral research in 2025?
The company advanced proprietary antivirals, noting orally active, non‑covalent PLpro inhibitors with dose‑dependent activity in SARS‑CoV‑2 infected mice. According to the company, candidates showed cellular potency and favorable pharmacokinetics.
